Article Information
History
- December 14, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Dean Follmann, PhD1,*,
- Jonathan Fintzi, PhD1,
- Michael P. Fay, PhD1,
- Holly E. Janes, PhD2,
- Lindsey Baden, MD3,
- Hana El Sahly, MD3a,
- Thomas R. Fleming, PhD4,
- Devan V. Mehrotra, PhD5,
- Lindsay N. Carpp, PhD2,
- Michal Juraska, PhD2,
- David Benkeser, PhD6,
- Deborah Donnell, PhD2,
- Youyi Fong, PhD2,
- Shu Han, PhD7,
- Ian Hirsch, PhD8,
- Ying Huang, PhD2,
- Yunda Huang, PhD2,
- Ollivier Hyrien, PhD2,
- Alex Luedtke, PhD9,
- Marco Carone, PhD4,
- Martha Nason, PhD1,
- An Vandebosch, PhD10,
- Honghong Zhou, PhD7,
- Iksung Cho, MS11,
- Erin Gabriel, PhD12,
- James G. Kublin, MD2,
- Myron S. Cohen, MD13,
- Lawrence Corey, MD2,14,
- Peter B. Gilbert, PhD2,4 and
- Kathleen M. Neuzil, MD15
- 1Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
- 2Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- 3Brigham and Women’s Hospital, Boston, MA, USA
- 3aBaylor College of Medicine, Houston, TX, USA
- 4Department of Biostatistics, University of Washington, Seattle, WA, USA
- 5Biostatistics and Research Decision Sciences, Merck & Co., Inc., North Wales, PA, USA
- 6Rollins School of Public Health, Emory University, Atlanta, GA, USA
- 7Moderna, Inc., Cambridge, MA, USA
- 8Biometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
- 9Department of Statistics, University of Washington, Seattle, WA, USA
- 10Janssen R&D, Janssen Pharmaceuticals NV, Beerse, Belgium
- 11Biostatistics, Novavax, Inc., Gaithersburg, MD, USA
- 12Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden
- 13Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA
- 14Departments of Medicine and Lab Medicine, University of Washington, Seattle, WA, USA
- 15University of Maryland School of Medicine, Baltimore, MD, USA
- ↵*Corresponding author; email: dfollmann{at}niaid.nih.gov
Posted December 14, 2020.
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials
